Media headlines about Biopharmx Corp (NYSE:BPMX) have trended somewhat positive on Thursday, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biopharmx Corp earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.6858787171182 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- BioPharmX Corporation (BPMX) noted a price change of 1.38% and … - Stocks Gallery (stocksgallery.com)
- Brokerages Expect Biopharmx Corp (BPMX) to Post ($0.07) EPS (americanbankingnews.com)
- What’s Behind the Numbers For Biopharmx Corp (BPMX)? - FLBC News (flbcnews.com)
- Latest Analysts Research Reports About BioPharmX Corporation (BPMX), Louisiana-Pacific Corporation (LPX) - Newburgh Gazette (newburghgazette.com)
- Biopharmx Corp (BPMX) Seeing Increased Volatility in Session - Stock Press Daily (stockpressdaily.com)
Shares of Biopharmx Corp (NYSE BPMX) traded down 1.3851% on Thursday, hitting $0.4699. 473,905 shares of the stock were exchanged. The company’s 50 day moving average is $0.48 and its 200-day moving average is $0.52. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $1.22. The stock’s market cap is $34.83 million.
Separately, ValuEngine raised shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 24th.
TRADEMARK VIOLATION NOTICE: This article was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://stocknewstimes.com/2017/07/20/biopharmx-corp-nysebpmx-earning-somewhat-positive-media-coverage-report-finds.html.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.
